HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: A systematic review

The Lancet Infectious Diseases

Volumn 11, Issue 10, 2011, Pages 769-779

  Sigaloff, Kim C E ^a   Calis, Job C J ^b   Geelen, Sibyl P ^d   van Vugt, Michèle ^c   de Wit, Tobias F Rinke ^a  

^a PharmAccess Foundation   (Netherlands)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

CHILDHOOD DISEASE; CITATION ANALYSIS; DATA EXTRACTION; DEVELOPING COUNTRY; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE;

ADOLESCENT; AFRICA; ANTI-HIV AGENTS; ASIA; BENZOXAZINES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; FEMALE; HEALTH RESOURCES; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; LATIN AMERICA; MALE; MUTATION; NEVIRAPINE; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; STAVUDINE; TREATMENT FAILURE; VIRAL LOAD; ZIDOVUDINE;

EID: 80053220672     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70141-4     Document Type: Review

References (85)

1. Newell ML Mechanisms and timing of mother-to-child transmission of HIV-1. AIDS 1998, 12:831-837.
2. Diaz C, Hanson C, Cooper ER, et al. Disease progression in a cohort of infants with vertically acquired HIV infection observed from birth: the Women and Infants Transmission Study (WITS). J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18:221-228.
3. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003, 362:1605-1611. HIV Paediatric Prognostic Markers Collaborative Study Group.
4. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004, 364:1236-1243.
5. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001, 345:1522-1528.
6. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral herapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000, 284:190-197.
7. Sanchez JM, Ramos Amador JT, Fernandez de Miguel S, et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003, 22:863-867.
8. Towards universal access: scaling up HIV services for women and children in the health sector. Progress report 2009 UNICEF, UNAIDSUNAIDS, WHOWHO, (accessed June 23, 2011). http://www.who.int/hiv/pub/2009progressreport/en/index.html.
9. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach: 2010 revisions) WHO, (accessed June 23, 2011). http://www.who.int/hiv/pub/paediatric/infants2010/en/index.html.
10. van Rossum AM, Fraaij PLA, de Groot R Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2002, 2:93-102.
11. Response to combination antiretroviral therapy: variation by age. AIDS 2008, 22:1463-1473. COHERE.
12. Walker AS, Doerholt K, Sharland M, Gibb DM Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV paediatric study. AIDS 2004, 18:1915-1924.
13. Abrams EJ, Weedon J, Steketee RW, et al. Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group. J Infect Dis 1998, 178:101-108.
14. Menson EN, Walker AS, Sharland M, et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. BMJ 2006, 332:1183-1187.
15. Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics 2007, 119:e1371-e1383.
16. 2009 AIDS Epidemic update UNAIDS, (accessed June 23, 2011). http://www.unaids.org/en/dataanalysis/epidemiology/2009aidsepidemicupdate/.
17. Moorthy A, Gupta A, Bhosale R, et al. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS One 2009, 4:e4096.
18. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009, 17:138-145.
19. Systematic reviews in health care: meta-analysis in context 2001, BMJ Publishing Group, London. 2nd edn. M. Egger, G.D. Smith, D. Altman (Eds.).
20. Villar J, Mackey ME, Carroli G, Donner A Meta-analysis in systematic review of randomized controlled trials in perinatal medicine: comparison of fixed and random effects models. Stat Med 2001, 20:3635-3647.
21. Vignoles M, Barboni G, Agosti MR, Garcia M. High frequency of antiretroviral drug resistance and low percentage of drug detection in plasma in HIV-infected children with virological failure. Proceedings of the XVII International AIDS Conference; Mexico City, Mexico; Aug 3-8, 2008. Abstract MOPE0192.
22. Janssens B, Raleigh B, Soeung S, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: Evaluation at 12 months in a routine program in Cambodia. Pediatrics 2007, 120:E1134-E1140.
23. Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V Predictors of virologic failure and genotypic resistance mutation patterns in Thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J 2009, 28:826-830.
24. Gody JC, Charpentier C, Mbitikon O, et al. High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. J Acquir Immune Defic Syndr 2008, 49:566-569.
25. Chaix ML, Rouet F, Kouakoussui KA, et al. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire. Pediatr Infect Dis J 2005, 24:1072-1076.
26. Ichimura H, Lihana R, Lwembe R, et al. Antiretroviral therapy failure and drug resistance-associated mutations among non-B subtype HIV-1-infected Kenyan children. Proceedings of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; July 19-22, 2009. Abstract WEPEA090.
27. Germanaud D, Derache A, Traore M, et al. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. J Antimicrob Chemother 2010, 65:118-124.
28. Vaz P, Chaix ML, Jani I, et al. Risk of Extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure. Pediatr Infect Dis J 2009, 28:e283-e287.
29. Sunpath H, Zanoni B, Marconi V, et al. Longitudinal analysis of a pediatric cohort who failed first-line HAART in an antiretroviral roll-out site in KwaZulu Natal, South Africa. Proceedings of the 16th Conference on Retroviruses and Opportunistic Infections; Feb 8-11, 2009; Montréal, Canada; Feb 8-11, 2009. Abstract 888.
30. Hunt G, Taylor B, Coovadia A, et al. Development of drug resistance among a cohort of HIV-infected infants exposed to nevirapine for prevention of mother-to-child transmission initiating PI-based ART in South Africa. Proceedings of the 16th Conference on Retroviruses and Opportunistic Infections; Montréal, Canada; Feb 8-11, 2009. Abstract 957.
31. Musiime V, Ssali F, Kayiwa J, et al. Response to nonnucleoside reverse transcriptase inhibitor-based therapy in hiv-infected children with perinatal exposure to single-dose nevirapine. AIDS Res Hum Retroviruses 2009, 25:989-996.
32. Achan J, Ruel T, Li P, et al. Incidence of early virological failure and the evolution of antiretroviral drug (ARV) resistance mutations in ugandan children. Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, USA; Feb 16-19, 2010. Abstract 889.
33. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007, 46:187-193.
34. Ahoua L, Guenther G, Pinoges L, et al. Children's antiretroviral treatment outcomes after 12 or 24 months of HAART in an HIV care program of North-western Uganda. Proceedings of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Sydney, Australia; July 22-25, 2007. Abstract TUPEB132.
35. Gupta RK, Ford D, Kabamba D, et al. Two year virological outcomes in HIV-1 infected Zambian children using adult Triomune (fixed dose combination d4T, 3TC and NVP). Proceedings of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; July 19-22, 2009. Abstract MOPEB056.
36. Mecikovsky D, Aulicino P, Rocco C, et al. Antiretroviral drug resistance among HIV infected children failing treatment in Argentina. Proceedings of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; July 19-22, 2009. Abstract WEPEB212.
37. Simonetti SRR, Schatzmayr HG, Simonetti PP Human immunodeficiency virus type 1: Drug resistance in treated and untreated Brazilian children. Mem Inst Oswaldo Cruz 2003, 98:831-837.
38. Machado DM, Fernandes SC, Succi RC, et al. Analysis of HIV- type 1 protease and reverse transcriptase in Brazilian children failing highly active antiretroviral therapy (HAART). Rev Inst Med Trop Sao Paulo 2005, 47:1-5.
39. de Oliveira CM, Almeida FJ, Rodrigues R, et al. High frequency of BF mosaic genomes among HIV-1-infected children from Sao Paulo, Brazil. Arch Virol 2008, 153:1799-1806.
40. Barrero-Barreto R, Rodriguez-Diaz R, Munoz-Hernandez R, et al. Antiretroviral drug resistance profile among mexican HIV-infected children. Proceedings of the XVII International AIDS Conference; Mexico City, Mexico; Aug 3-8, 2008. Abstract MOPDA205.
41. Sophan S, Vibol U, Chantheany H, et al. Lopinavir/ritonavir-based second line antiretroviral treatment in children at National Pediatric Hospital, Phnom Penh, Cambodia. Proceedings of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; July 19-22, 2009. Abstract CDD020.
42. Zhang F, Haberer J, Wei H, et al. Drug resistance in the Chinese National Pediatric Highly Active Antiretroviral Therapy Cohort: implications for paediatric treatment in the developing world. Int J STD AIDS 2009, 20:406-409.
43. Sungkanuparph S, Apiwattanakul N, Thitithanyanont A, Chantratita W, Sirinavin S HIV-1 drug resistance mutation in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Southeast Asian J Trop Med Public Health 2009, 40:83-88.
44. van Zyl GU, van der Merwe L, Claassen M, et al. Protease inhibitor resistance in South African children with virological failure. Pediatr Infect Dis J 2009, 28:1125-1127.
45. Page TN, Archary M, Gordon M, et al. Drug resistance patterns and genotypic analysis of viral tropism in HIV-1 subtype C-infected children failing antiretroviral therapy in South Africa. Proceedings of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; July 19-22, 2009. Abstract TUPEB094.
46. Pillay V, Pillay C, Kantor R, Venter F, Levin L, Morris L HIV Type 1 Subtype C Drug Resistance among Pediatric and Adult South African Patients Failing Antiretroviral Therapy. AIDS Res Hum Retroviruses 2008, 24:1449-1454.
47. Riddick A, Moultrie H, Kuhn L, Fairlie L, Chersich M, Meyers T. Genotypic resistance profiles among HIV-1 infected children failing antiretroviral treatment at Chris Hani Baragwanath Hospital, Soweto, South Africa. Proceedings of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; July 19-22, 2009. Abstract WEPEB213.
48. Wallis CL, Varughese S, Technau K, Stevens W. HIV drug resistant mutations in HIV-1 sybtype C children failing antiretroviral therapy in South-Africa. Proceedings of the XVIII International HIV Drug Resistance Workshop; Fort Myers, FL, USA; June 9-13, 2009. Abstract A184.
49. Kebe K, Diop Ndiaye H, Diagne Gueye NR, et al. HIV-1 drug resistance and genetic diversity among children attending the paediatric hospital Albert Royer of Dakar. Rev Antivir Ther 2009, 6:34-35.
50. Kekitiinwa A, Friedman D, Coakley E, Lie Y, Graziano F. Profiling Etravirine Resistance in Ugandan Children with Extended Failure of a NNRTI-inclusive Regimen as First-line ART. Proceedings of the 16th Conference on Retroviruses and Opportunistic Infections; Montréal, Canada; Feb 8-11, 2009. Abstract 891.
51. Delaugerre C, Warszawski J, Chaix ML, et al. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children. J Med Virol 2007, 79:1261-1269.
52. Chakraborty R, Smith CJ, Dunn D, et al. HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J 2008, 27:457-459.
53. Mullen J, Leech S, O'Shea S, et al. Antiretroviral drug resistance among HIV-1 infected children failing treatment. J Med Virol 2002, 68:299-304.
54. Figueiredo Saad F, Kaminami Morimoto H, Wiechmann SL, et al. Frequency and diversity of human immunodeficiency virus type 1 mutations associated with antiretroviral resistance among patients from Southern Brazil failing highly active antiretroviral therapy (HAART). Int J Mol Med 2010, 26:585-593.
55. Ait-Khaled M, Stone C, Amphlett G, et al. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 2002, 16:1686-1689.
56. Guia de Tratamento Clínico da Infecção pelo HIV em crianças Ministério da Saúde, Coordenação Nacional de DST e AIDSCoordenação Nacional de DST e AIDS, (accessed June 23, 2011). http://bvsms.saude.gov.br/bvs/publicacoes/073_03Guia_tratamento.pdf.
57. Recomendações para Profilaxia da Transmissão Vertical do HIV e Terapia Anti-Retroviral em Gestantes Ministério da Saúde, Coordenação Nacional de DST e AIDSCoordenação Nacional de DST e AIDS, (accessed June 23, 2011). http://www.saude.sp.gov.br/resources/profissional/documentos_tecnicos/informes_tecnicos/consensogestantes2006_05julho2006.pdf.
58. Recomendaciones para la prevencion de la transmision perinatal del VIH Argentina Ministerio de Salud, Unidad Coordinadora Ejecutora De VIH/SIDA/ETSUnidad Coordinadora Ejecutora De VIH/SIDA/ETS, (accessed June 23, 2011). http://www.msal.gov.ar/htm/site/promin/UCMISALUD/publicaciones/pdf/08-HIV.pdf.
59. Guía de manejo antirretroviral de las personas con VIH, 4th edn Centro Nacional para la Prevención y Control del VIH/SIDA, (accessed June 23, 2011). http://www.portalsida.org/Article_Details.aspx?ID=8952.
60. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998, 177:557-564.
61. Coffie PA, Ekouevi DK, Chaix ML, et al. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin Infect Dis 2008, 46:611-621.
62. Greco DB, Simao M Brazilian policy of universal access to AIDS treatment: sustainability challenges and perspectives. AIDS 2007, 21:S37-S45.
63. Bergshoeff AS, Fraaij PL, van Rossum AM, et al. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications. Antivir Ther 2003, 8:215-222.
64. Curras V, Hocht C, Mangano A, et al. Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children. Pharmacology 2009, 83:59-66.
65. Scaling up antiretroviral treatment: Lessons learnt from Thailand. Report of an external evaluation WHO, Regional Office for South-East AsiaRegional Office for South-East Asia, (accessed June 23, 2010). http://www.searo.who.int/LinkFiles/Publications_Scaling-up.pdf.
66. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008, 46:1589-1597.
67. Brenner BG, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006, 20:F9-13.
68. Martinez-Cajas JL, Pant-Pai N, Klein MB, Wainberg MA Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev 2008, 10:212-223.
69. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood E HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009, 14:523-531.
70. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009, 23:1127-1134.
71. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009, 9:409-417.
72. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010, 10:155-166.
73. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001, 15:1951-1957.
74. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007, 356:135-147.
75. Moorthy A, Kuhn L, Coovadia A, et al. Plasma frequencies of nevirapine resistance influence virologic responses to nevirapine maintenance therapy in single-dose exposed HIV-infected children initially treated with lopinavir HAART. Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, USA; Feb 16-19, 2010. Abstract 159.
76. Palumbo P, Violari A, Lindsey J, et al. Nevirapine (NVP) vs lopinavir-ritonavir (LPV/r)-based antiretroviral therapy (ART) in single dose nevirapine (sdNVP)-exposed HIV-infected infants: preliminary results from the IMPAACT P1060 trial. Proceedings of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; July 19-22, 2009. Abstract LBPEB12.
77. Walsh JC, Pozniak AL, Nelson MR, Mandalia S, Gazzard BG Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr 2002, 30:278-287.
78. Vigano A, Meroni L, Marchetti G, et al. Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1. Antivir Ther 2008, 13:839-843.
79. Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 2005, 116:e846-e854.
80. Riordan A, Judd A, Boyd K, Cliff D, Doerholt K, Lyall H, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. Pediatr Infect Dis J 2009, 28:204-209.
81. Kosalaraksa P, Bunupuradah T, Engchanil C, et al. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Pediatr Infect Dis J 2008, 27:623-628.
82. Descamps D, Lambert-Niclot S, Marcelin AG, et al. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. J Antimicrob Chemother 2009, 63:585-592.
83. Neely M, Kovacs A Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir. Ther Clin Risk Manag 2009, 5:595-615.
84. Salazar JC, Cahn P, Yogev R, et al. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents. AIDS 2008, 22:1789-1798.
85. Wiznia A, Samson P, Acosta E. Safety and efficacy of raltegravir in pediatric HIV infection: preliminary analysis from the international maternal pediatric adolescent AIDS clinical trial group, P1066. Proceedings of the 16th Conference on Retroviruses and Opportunistic Infections; Montréal, Canada; Feb 8-11, 2009. Abstract 874.